natgillin/translations-raw huggingface dataset:
A lipid compound according to claim 1, wherein R2 and R3 are independently selected from a hydrogen atom or an ethyl group; or R2 and R3 are connected to form a cyclobutane group. 
Lipidni pripravak prema zahtjevu 1, naznačen time da R2 i R3 su neovisno odabrani od vodikovog atoma ili etilne skupine; ili R2 i R3 su spojeni tako da tvore ciklobutansku skupinu.
A compound according to claim 1, wherein R1 is a C14-C22 alkenyl group having the first double bond at the third carbon-carbon bond from the omega (ω) end of the carbon chain. 
Spoj prema zahtjevu 1, naznačen time da R1 je C14-C22 alkenil skupina koja ima prvu dvostruku vezu na trećoj vezi ugljik-ugljik od omega (ω) kraja ugljikovog lanca.
A compound according to claim 9, wherein R1 is a C14-C22 alkenyl with 5-6 double bonds. 
Spoj prema zahtjevu 9, naznačen time da R1 je C14-C22 alkenil s 5-6 dvostrukih veza.
X represents a carboxylic acid or a carboxamide selected from the group consisting of N-methyl carboxamide, N,N-dimethyl carboxamide, N-ethyl carboxamide and N,N-diethyl carboxamide; and Y is sulfoxide or sulfone. 
X predstavlja karboksilnu kiselinu ili karboksamid odabran iz skupine koju čine N-metil karboksamid, N,N-dimetil karboksamid, N-etil karboksamid i N,N-dietil karboksamid; i Y je sulfoksid ili sulfon.
A pharmaceutical composition according claim 24, further comprising a pharmaceutically acceptable carrier, excipient or diluent, or any combination thereof. 
Farmaceutski pripravak prema zahtjevu 24, naznačen time da dodatno sadrži farmaceutski prihvatljiv nosač, pomoćno sredstvo ili razrjeđivač, ili njihovu kombinaciju.
A pharmaceutical composition according to claim 26, in the form of a capsule or a tablet. 
Farmaceutski pripravak prema zahtjevu 26, naznačen time da je u obliku kapsule ili tablete.
A lipid compound according to claim 42, wherein said fatty liver disease is nonalcoholic fatty liver disease (NAFLD). 
Lipidni pripravak prema zahtjevu 42, naznačen time da navedena bolest masne jetre je nealkoholna bolest masne jetre (NAFLD).
hypertriglyceridemia (HTG); prevention and/or treatment of elevated triglyceride levels, LDL cholesterol levels, and/or VLDL cholesterol levels; prevention and/or treatment of obesity or an overweight condition; reduction of body weight and/or for preventing body weight gain; treatment and/or the prevention of a fatty liver disease, e.g. 
hipertrigliceridemije (HTG); sprječavanje i/ili liječenje povišenih razina triglicerida, razina LDL kolesterola, i/ili razina VLDL kolesterola; sprječavanje i/ili liječenje pretilosti ili stanja prekomjerne težine; smanjenje tjelesne težine i/ili za sprječavanje dobivanja na tjelesnoj težini; liječenje i/ili sprječavanje bolesti masne jetre, npr.
nonalcoholic fatty liver disease (NAFLD); treatment and/or the prevention of atherosclerosis; prevention of myocardial infarction; treatment and/or the prevention of peripheral insulin resistance and/or a diabetic condition, e.g. 
nealkoholna bolest masne jetre (NAFLD); liječenje i/ili sprječavanje ateroskleroze; sprječavanje infarkta miokarda; liječenje i/ili sprječavanje periferne inzulinske rezistencije i/ili dijabetičkog stanja, npr.
type 2 diabetes; reduction of plasma insulin, blood glucose and/or serum triglycerides; or treatment and/or the prevention of an inflammatory disease or condition. 
dijabetesa tipa 2; smanjenje inzulina u plazmi, glukoze u krvi i/ili triglicerida u serumu; ili liječenje i/ili sprječavanje upalne bolesti ili stanja.
A pharmaceutical composition according claim 52, further comprising a pharmaceutically acceptable carrier, excipient or diluent, or any combination thereof. 
Farmaceutski pripravak prema zahtjevu 52, naznačen time da dodatno sadrži farmaceutski prihvatljiv nosač, pomoćno sredstvo ili razrjeđivač, ili bilo koju njihovu kombinaciju.
A method for the production of a lipid compound according to any one of the claims 1-19, comprising one of the following methods: Method I wherein R1, R2, R3 and X are as defined in claims 1-19, and LG represents a leaving group such as mesylate, tosylate or a suitable halogen; 
Postupak za proizvodnju lipidnog spoja prema bilo kojem od zahtjeva 1-19, naznačen time da sadrži jedan od slijedećih postupaka: Postupak I [image] pri čemu R1, R2, R3 i X su kako je definirano u zahtjevima 1-19, i LG predstavlja odlazeću skupinu kao što je mezilat, tozilat ili odgovarajući halogen;
Method II wherein R1, R2, R3 and X are as defined in claims 1-19. 
Postupak II [image] pri čemu R1, R2, R3 i X su kako je definirano u zahtjevima 1-19.
The method according to claim 56, wherein the raw material may originate from a vegetable, a microbial and/or an animal source. 
Postupak prema zahtjevu 56, naznačen time da sirovi materijal može potjecati iz biljnog, mikrobnog i/ili životinjskog izvora.
The method according to claim 57, wherein the animal source is a marine oil, a fish oil or a krill oil. 
Postupak prema zahtjevu 57, naznačen time da životinjski izvor je ulje morskih životinja, riblje ulje ili ulje od krila.
n is independently 0 or 1; 
n je neovisno 0 ili 1;
m is independently 0 or 1; 
m je neovisno 0 ili 1;
or Ra and Rb together with the carbon atom they are attached form a C3-6cycolalkyl group; 
ili Ra i Rb, zajedno s atomom ugljika na kojeg su vezani, tvore C3-6cikloalkilnu skupinu;
or Ra and Rb together with the carbon atom they are attached to form a C3-6 cycloalkyl group; 
ili Ra i Rb, zajedno s atomom ugljika na kojeg su vezani, tvore C3-6cikloalkilnu skupinu;
m is independently 0 or 1; p is independently 1 or 2; and y is 1 or 2; 
m je neovisno 0 ili 1; p je neovisno 1 ili 2; i y je 1 ili 2;
A compound for use according to claim 12 wherein the disease is congestive heart failure. 
Spoj, namijenjen upotrebi u skladu s patentnim zahtjevom 12, naznačen time što je bolest kongestivna srčana insuficijencija.
A compound for use according to claim 12 wherein the disease is acute lung injury. 
Spoj, namijenjen upotrebi u skladu s patentnim zahtjevom 12, naznačen time što je bolest akutna ozljeda pluća.
The pharmaceutical composition according to claim 8 or claim 9, wherein the cancer is selected from the group consisting of lung cancer, prostate cancer, thyroid cancer, stomach cancer, liver cancer, ovarian cancer, colon cancer, breast cancer, pancreatic cancer, uterine cancer, melanoma, glioblastoma, and blood cell cancer. 
Farmaceutska kompozicija prema patentnom zahtjevu 10 ili 11, gdje je rak odabran iz grupe koja se sastoji od raka pluća, raka prostate, tiroidnog raka, raka želuca, raka jetre, raka jajnika, raka debelog crijeva, raka dojke, raka gušterače, raka materice, melanoma, glioblastoma, i raka krvnih stanica.
A product selected from the group consisting of paclitaxel, carboplatin, CPT-11, vinblastine, and 5-FU for use in the treatment and/or prevention of cancer characterized by simultaneously or sequentially administering an antibody or functional fragment thereof having antigen-binding activity according to any one of claims 1 to 8. 
Proizvod odabran iz grupe koja se sastoji od paklitaksela, karboplatine, CPT-11, vinblastina, i 5-FU za primjenu u liječenju i/ili prevenciji raka naznačeno simultanom ili sekvencija1nom administracijom antitijela ili njegovog funkciona1nog fragmenta koji posjeduje aktivnost vezivanja antigena prema bilo kojem od patentnih zahtjeva 1 do 8.
The antibody or product for use according to any one of claims 13 to 15, wherein the cancer is selected from the group consisting of lung cancer, prostate cancer, thyroid cancer, stomach cancer, liver cancer, ovarian cancer, colon cancer, breast cancer, pancreatic cancer, renal cancer, uterine cancer, melanoma, fibrosarcoma, glioblastoma, and blood cell cancer. 
Antitijelo ili proizvod za primjenu prema bilo kojem od patentnih zahtjeva 13 do 15, gdje je rak odabran iz grupe koja se sastoji od raka pluća, raka prostate, tiroidnog raka, raka želuca, raka jetre, raka jajnika, raka debelog crijeva, raka dojke, raka gušterače, raka materice, melanoma, glioblastoma, i raka krvnih stanica..
An ALK inhibitor comprising as an active ingredient the compound according to any one of Claims 1 to 5, or a salt or solvate thereof. 
Inhibitor ALK, naznačen time što kao aktivni sastojak sadrži spoj u skladu s patentnim zahtjevom 1, ili njegovu sol ili solvat.
A pharmaceutical for the prophylaxis or treatment of cancer, cancer metastasis, depression or cognitive function disorder, comprising as an active ingredient the compound according to any one of Claims 1 to 5, or a salt or solvate thereof. 
Farmaceutska tvar namijenjena profilaksi ili liječenju raka, metastaza raka, depresije ili poremećaja kognitivnih funkcija, naznačena time što kao aktivni sastojak sadrži spoj u skladu s patentnim zahtjevom 1, ili njegovu sol ili solvat.
The fuel gas supply system of a vessel according to claim 1 wherein the gasifying device includes a heater. 
Sustav dobave pogonskog plina za plovilo prema zahtjevu 1 naznačen time da uređaj za uplinjavanje sadrži grijač.
The fuel gas supply system of a vessel according to claim 2 wherein the boil-off gas is in thermal communication with the LNG to minimize the capacity of the boil-off gas reliquefaction apparatus. 
Sustav dobave pogonskog plina za plovilo prema zahtjevu 1 naznačen time da je ispareni plin u termalnoj komunikaciji s LNG kako bi se smanjio kapacitet uređaja za ukapljivanje isparenog plina.
A method according to claim 9, wherein the speed of the pressing assembly in the direction of travel of the board is matched to the speed of the board by means of a Hoekens linkage. 
Postupak prema zahtjevu 9, naznačen time da je brzina pritisnog sklopa (10) u smjeru pomicanja ploče (100) usklađena s brzinom ploče pomoću Hoekensovog povezivanja.
A method according to claim 9, wherein the speed of the pressing assembly in the direction of travel of the board is matched to the speed of the board by means of a hypotrochoid motion. 
Postupak prema zahtjevu 9, naznačen time da je brzina pritisnog sklopa (10) u smjeru pomicanja ploče (100) usklađena sa brzinom ploče pomoću hipotrohoidnog gibanja.
The formulation according to claim 1, which comprises as active ingredients only the combination formoterol fumarate dihydrate and beclometasone dipropionate. 
Formulacija prema patentnom zahtjevu 1, koja sadrži kao aktivne sastojke samo kombinaciju formoterol-fumarat dihidrata i beklometazon-dipropionata.
The formulation according to claim 12 which is capable of delivering 6 µg formoterol fumarate dihydrate and 100 µg beclometasone dipropionate per actuation. 
Formulacija prema patentnom zahtjevu 12 koja je sposobna isporučiti 6 µg formoterol-fumarat dihidrata i 100 µg beklometazon-dipropionata po pokretanju.
A pharmaceutical aerosol formulation for use in pressurized metered dose inhalers which is capable of delivering 6 µg formoterol fumarate dihydrate and 100 µg beclometasone dipropionate per actuation, said formulation comprising: 
Farmaceutska aerosolna formulacija prema patentnom zahtjevu 1 za upotrebu u inhalatorima sa stlačenim inhalatom koji je sposoban isporučiti 6 µg formoterol-fumarat dihidrata i 100 µg beklometazon-dipropionata po pokretanju, a rečena formulacija sadrži:
from 0.002 and 0.05% w/w oleic acid; characterized in that HFA 134a is the sole propellant and formoterol fumarate dihydrate is suspended in a micronised form in the formulation while beclometasone dipropionate is fully dissolved. 
od 0.002 te 0.05% w/w oleinske kiseline; naznačena time da je HFA 134a jedini propelant te da je formoterol-fumarat dihidrat suspendiran u formulaciji u usitnjenom obliku dok je beklometazon-dipropionat potpuno otopljen.
A pressurized metered dose inhaler comprising a canister filled with the pharmaceutical aerosol formulation of any one of the claims 1 to 14, and a metering valve for delivering therapeutically effective doses of the active ingredients. 
Inhalator sa stlačenim inhalatom koji sadrži spremnik napunjen farmaceutskom aerosolnom formulacijom iz bilo kojeg od patentnih zahtjeva 1 do 14, te odmjerni ventil za isporuku terapijski učinkovitih doza aktivnih sastojaka.
The pressurized metered dose inhaler according to claim 17, wherein metering valve is capable of delivering a volume of 50 or 63 µl. 
Inhalator sa stlačenim inhalatom prema patentnom zahtjevu 17, naznačen time da je odmjerni ventil sposoban isporučiti volumen od 50 ili 63 µl.
The pharmaceutical aerosol formulation of any one of the claims 1 to 14 for use for the prevention and/or treatment of mild, moderate or severe, acute or chronic symptoms or for prophylactic treatment of a respiratory disease. 
Farmaceutska aerosolna formulacija iz bilo kojeg od patentnih zahtjeva 1 do 14 za upotrebu za prevenciju i/ili liječenje blagih, umjerenih ili ozbiljnih, akutnih ili kroničnih simptoma ili za profilaktičko liječenje respiratornih bolesti.
An assembly according to any one of the preceding claims, wherein the drive means (20) is arranged to accelerate the pressing head (16) and the support member (17) in the first direction to a speed which substantially matches a speed of the moving board (100). 
Sklop prema bilo kojem od prethodnih zahtjeva, naznačen time da su pogonska sredstva (20) postavljena tako da ubrzaju pritisnu glavu (16) i potporni element (17) u prvom smjeru na brzinu koja uglavnom odgovara brzini ploče (100) koja se kreće.
A method for forming a depression within a moving, wet gypsum board (100), the method comprising the use of a pressing assembly (10), the method comprising the steps of 
Postupak za formiranje udubljenja unutar pomične, vlažne ploče od gipsa (100), te postupak sadrži korištenje pritisnog sklopa (10), pri čemu postupak sadrži korake
providing a gypsum board (100); 
pripremanje ploče od gipsa (100);
causing the pressing assembly to compress the board to substantially simultaneously form a first depression (106) and a second depression (107), the first and second depressions being located either side of a comparatively uncompressed board portion (108). 
koji uzrokuje da pritisni sklop komprimira ploču do uglavnom istovremeno do prvog udubljenja (106) i drugog udubljenja (107), te su prvo i drugo udubljenje smješteni s bilo koje strane relativno ne stlačenog dijela ploče (108).
A method according to claim 14 wherein the silicone oil is present in an amount of 100-1200 g/m3. 
Postupak prema zahtjevu 14 naznačen time da je silikonsko ulje prisutno u količini od 100-1200 g/m3.
A medicament comprising as an active ingredient the compound according to claim 1, or a salt or solvate thereof. 
Medikament, naznačen time što kao aktivni sastojak sadrži spoj u skladu s patentnim zahtjevom 1, ili njegovu sol ili solvat.
An ALK inhibitor comprising as an active ingredient the compound according to claim 1, or a salt or solvate thereof. 
Inhibitor ALK, naznačen time što kao aktivni sastojak sadrži spoj u skladu s patentnim zahtjevom 1, ili njegovu sol ili solvat.
A pharmaceutical for the prophylaxis or treatment of cancer, cancer metastasis, depression or cognitive function disorder, comprising as an active ingredient the compound according to claim 1, or a salt or solvate thereof. 
Farmaceutska tvar namijenjena profilaksi ili liječenju raka, metastaza raka, depresije ili poremećaja kognitivnih funkcija, naznačena time što kao aktivni sastojak sadrži spoj u skladu s patentnim zahtjevom 1, ili njegovu sol ili solvat.
a fuel gas supply line connected from the LNG tank (1) to the high-pressure gas injection engine of the ship; 
Sustav dobave pogonskog plina za plovilo osim za LNG tanker, koji sadrži: spremnik LNG (1); visokotlačni plinski injekcijski motor;
The fuel gas supply system of a ship according to claim 1 wherein the gasifying means is a heater. 
Sustav dobave pogonskog plina za plovilo prema zahtjevu 1 naznačen time da uređaj za uplinjavanje sadrži grijač.
a fuel gas supply line (L1) connected from the LNG tank to the high-pressure gas injection engine of the vessel, 
vod za dobavu pogonskog plina spojen iz spremnika LNG (1) do visokotlačnog plinskog injekcijskog motora za brod;
a boil-off gas reliquefaction apparatus operable to reliquefy boil-off gas generated in the LNG tank including a heat exchanger (3) installed along the fuel gas supply line between the LNG tank and the high-pressure gas injection engine, and wherein the boil-off gas from an upper portion of the LNG tank (1) is in thermal communication with the compressed LNG while passing through the heat exchanger and then is supplied to the fuel gas supply line. 
Sustav dobave pogonskog plina za brod prema zahtjevu 3, naznačen time da dodatno sadrži: izmjenjivač topline (3) instaliran nizvodno od jedne crpke u vodu za opskrbu pogonskim plinom; i vod za ukapljivanje isparenog plina spojen iz gornjeg dijela spremnika LNG, koji prolazi kroz izmjenjivač topline, do jedne strane spremnika LNG, te je vod za ukapljivanje isparenog plina konfiguriran da ukapljuje ispareni plin koji je nastao u spremniku LNG.
Shark-like chondroitin sulphate according to any of claims 1 to 3, for use in the prevention or treatment of osteoarthritis, or for the maintenance of musculoskeletal health. 
Kondroitin-sulfat sličan onom iz morskog psa u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je namijenjen upotrebi u sprječavanju ili liječenju osteoartritisa, ili za održavanje zdravlja mišićno-koštanog sustava.
A composition according to the previous claim, for use in the prevention or treatment of osteoarthritis, or for the maintenance of musculoskeletal health. 
Pripravak u skladu s prethodnim patentnim zahtjevom, naznačen time što je namijenjen upotrebi u sprječavanju ili liječenju osteoartritisa, ili za održavanje zdravlja mišićno-koštanog sustava.
salifying unsulphated chondroitin, prepared by defructosilating the E. coli K4 capsular polymer obtained by fermentation, as free acid, previously dissolved in an aqueous environment, with a salt selected from the group consisting of tetramethyl-, tetraethyl- and tetrabutyl-, ammonium or pyridinium; 
osoljavanju nesulfatiranog kondroitina, pripravljenog defruktoziliranjem kapsularnog polimera iz bakterije E. coli K4, dobivenog fermentiranjem, u obliku slobodne kiseline, prethodno otopljene u vodenom mediju, solju koju se bira iz skupine koju čine tetrametil-, tetraetil- i tetrabutil-, amonij ili piridinij;
drying the salified unsulphated chondroitin, as free acid and/or sodium salt, resulting from step a) till 5-15% of water content; 
sušenju osoljenog nesulfatiranog kondroitina, u obliku slobodne kiseline i/ili soli s natrijem, dobivenog u koraku a) do 5-15% sadržaj vode;
drying the salified unsulphated chondroitin resulting from step b), at a temperature of 100 °C-170 °C, till 0.1-3% of water content; 
sušenju osoljenog nesulfatiranog kondroitina dobivenog u koraku b), na temperaturi od 100 °C-170 °C, do sadržaja vode od 0,1-3%;
selectively sulphating the 6-position of the salified unsulphated chondroitin resulting from step c), solubilized in N-methyl pyrrolidone or dimethylformamide, at a temperature of 0°C-30°C, by adding 1-2 equivalents of sulphur trioxide pyridine complex or sulphur trioxide dimethylformamide complex, at time intervals of 1-3 hours, till a total of 2-15 equivalents of sulphur trioxide pyridine complex or sulphur trioxide dimethylformamide complex, is added; leaving the resulting solution under stirring for 2-24h; 
selektivnom sulfatiranju na položaju 6 osoljenog nesulfatiranog kondroitina dobivenog u koraku c), solubiliziranog u N-metilpirolidonu ili dimetilformamidu, na temperaturi od 0 °C-30 °C, uz dodavanje 1-2 ekvivalenta kompleksa sumporni trioksid–piridin ili kompleksa sumporni trioksid–dimetilformamid, u vremenskim intervalima od 1-3 sata, dok se ne doda ukupno 2-15 ekvivalenata kompleksa sumporni trioksid–piridin ili kompleksa sumporni trioksid–dimetilformamid; dobivenu otopinu se ostavi stajati 2-24 sata, uz miješanje;
quenching the reaction carried out in step d) with an aqueous sodium bicarbonate or carbonate solution, filtering and concentrating to dryness the resulting solution to obtain a dried solid; 
gašenju reakcije provedene u koraku d) vodenom otopinom natrijevog bikarbonata ili karbonata, filtriranju i koncentriranju do suhog dobivene otopine kako bi se dobilo osušenu krutinu;
dissolving the dried solid in an aqueous sodium chloride solution, ultrafiltrating and dialysing the resulting solution; 
otapanju osušene krutine u vodenoj otopini natrijevog klorida, ultrafiltriranju i dijaliziranju dobivene otopine;
purifying the product resulting from step g) and obtaining the latter either in acidic form or as the sodium salt thereof; 
pročišćavanju produkta dobivenog u koraku g) i dobivanju potonjeg bilo u obliku kiseline ili u obliku njegove sol s natrijem;
Process according to the previous claim wherein the salification of unsulphated chondroitin in step a) is carried out with a salt selected from the group consisting of tetramethyl-, tetraethyl- and tetrabutyl- ammonium. 
Postupak u skladu s prethodnim patentnim zahtjevom, naznačen time što se osoljavanje nesulfatiranog kondroitina u koraku a) provodi solju koju se bira iz skupine koju čine tetrametil-, tetraetil- i tetrabutilamonij.
Process according to the previous claim, wherein the selective sulphating in step d) is carried out adding a total of 2-4 equivalents of sulphur trioxide dimethylformamide complex. 
Postupak u skladu s prethodnim patentnim zahtjevom, naznačen time što se selektivno sulfatiranje u koraku d) provodi uz dodavanje ukupno 2-4 ekvivalenta kompleksa sumporni trioksid–dimetilformamid.
metallating an iodobromobenzyl derivative of Formula 57 with a Grignard reagent or halogen-metal exchange with an alkyllithium and reacting with a protected azetidinone in a one-pot process or in a step-wise process to provide a compound of Formula 58, wherein Y2 is bromine, chlorine, iodine, hydroxyl, or a sulfonate leaving group; 
metalaciji jodbrombenzilnog derivata Formule 57 Grignardovim reagensom ili halogen-metalnom izmjenom s alkillitijem i reakciji sa zaštićenim azetidinonom u postupku u jednoj posudi ili u postupku u više koraka kako bi se dobilo spoj Formule 58, gdje je Y2 brom, klor, jod, hidroksil ili sulfonat kao izlazna skupina;
addition of hydroxylamine to a compound of Formula 60 and cyclization in the presence of a quinine based chiral catalyst to provide a compound of Formula 61; 
dodavanju hidroksilamina spoju Formule 60 i ciklizacije u prisutnosti kiralnog katalizatora na bazi kinina kako bi se dobilo spoj Formule 61;
removal of the azetidine protecting group of the compound of Formula 61 to provide a compound of Formula 62; and 
uklanjanju zaštitne skupine za azetidin iz spoja Formule 61 kako bi se dobilo spoj Formule 62; i [image]
A compound selected from the group consisting of 
Spoj, naznačen time što se bira iz skupine koju čine
A fuel gas supply system of a vessel for supplying fuel gas from an LNG tank (1), which stores LNG as fuel gas, to a high-pressure gas injection engine, comprising: a boil-off gas liquefaction line (L2) configured to extract boil-off gas generated in the LNG tank (1); 
Sustav dobave pogonskog plina za plovilo osim za LNG tanker, koji sadrži: spremnik LNG (1); visokotlačni plinski injekcijski motor; prvu crpku (2) konfiguriranu da stlačuje LNG iz spremnika LNG (1), te da dobavlja komprimirani LNG prema drugoj crpki (4);
a light chain variable domain comprising: 
varijabilnu domenu lakog lanca koja sadrži:
A composition according to claim 5 for use in treating 
Sastav u skladu s patentnim zahtjevom 5 za uporabu u liječenju
The composition of claim 10, wherein the inflammatory condition is selected from the group consisting of allergic asthma, allergic rhinosinusitis, allergic conjunctivitis, and atopic dermatitis. 
Sastav za uporabu u skladu s patentnim zahtjevom 11, pri čemu je upalno stanje odabrano iz grupe koja se sastoji od alergijske astme, alergijskog rinosinusitisa, alergijskog konjuktivitisa i atopijskog dermatitisa.
• said adherent cells secrete a higher level of at least one factor selected from the group consisting of SCF, Flt-3 and IL-6 higher than that secreted by adherent cells from placenta or adipose tissue grown in a 2D culture and/or 
luče višu razinu najmanje jednog faktora odabranog iz skupine koju čine SCF, IL-6, i Flt-3 od razine koja je izlučena s adherentnim stanicama iz tkiva posteljice uzgojenog u 2D kulturi; i/ili